Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Urine test and chat could help young men stay on HIV prevention

NCT ID NCT05353283

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new way to help young men who have sex with men (ages 18-30) take their daily HIV prevention pills consistently. Participants provided a urine sample that was tested right away for the HIV prevention drug, and then received a short counseling session based on the results. The goal was to see if this approach was acceptable and could improve long-term adherence. The study enrolled 63 participants and has been completed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Motivational interviewing counseling and point-of-care urine tenofovir test
What this could lead to
If successful, this approach could help young men who have sex with men stay on track with their daily HIV prevention pills, reducing new HIV infections.
What could go wrong
This was a small, completed study with only 63 participants, so results may not apply to everyone. The intervention is behavioral and may not work for all individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

63 people

The number who actually took part.

Started

Sep 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male sex at birth who has sex with men * Age 18-30 years-old * Currently receiving tenofovir-based oral PrEP * Plans to continue taking daily PrEP over the upcoming 3 months Exclusion Criteria: * Participant living with HIV * Age \> 30 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Risk reduction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Risk Reduction Behavior HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Risk reduction

Contacts and locations

Locations

  • University of California, San Francisco/San Francisco General Hospital

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.